MAP2K4 and neoplasm: In the context of targeting MAPK signaling, which is overexpressed in HCC and associated with tumor growth, the downregulation of mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) using shRNA led to reduced cell proliferation, S-phase cell cycle blockade and increased tumor apoptosis [108].